Real-world PFS after selective RET TKI in RET+ NSCLC was 5.9 months with chemotherapy, 6.8 with chemo-immunotherapy
Stephen V Liu summarised outcomes after selective TKI treatment in RET-positive NSCLC, reporting short progression-free survival and no responses to third-line therapy.
“Huge unmet need remains.”— Stephen V Liu, MD
Stephen V Liu, chief of hematology and oncology at Georgetown and MedStar Georgetown University Hospital, summarised outcomes after selective TKI treatment in RET-positive non-small cell lung cancer (NSCLC) in a post on X. He tagged the AACR journal account @CCR_AACR.
According to Liu, the response rate with subsequent therapy was 41%. Real-world progression-free survival (rwPFS) was 5.9 months with chemotherapy and 6.8 months with chemotherapy plus immunotherapy. Real-world overall survival (rwOS) was 18.5 months and 13.7 months respectively. Liu noted that the difference was not significant (p=ns).
Third-line therapy was most often a taxane, Liu wrote. In that setting rwPFS was 1.5 months and the response rate was 0%.
Liu concluded: "Huge unmet need remains."
Original source
“Huge unmet need remains.”
— Stephen V Liu, MD View the post on X